Prot # ACH625-003: A phase IIa, randomized, double-blind (subject and investigator blind, sponsor open) placebo-controlled trial to evaluate the safety, tolerability and antiviral activity of oral ACH-0141625 in combination with pegylated interferon alfa-

Project: Research project

Project Details

StatusFinished
Effective start/end date11/11/1011/11/13

Funding

  • PRA Health Sciences (ACH625-003)
  • Achillion Pharmaceuticals, Inc. (ACH625-003)